HALIFAX, Nova Scotia--(BUSINESS WIRE)--Series J First Preferred Share quarterly dividend in release dated July 13, 2026, should read: $0.39660 (instead of $0.265625). The updated release reads EMERA DECLARES QUARTERLY DIVIDENDS On July 13, 2026, the Board of Directors of Emera Inc. (TSX/NYSE: EMA) declared quarterly dividends on its common shares and First Preferred Shares, each of which is payable on and after August 17, 2026 to the applicable shareholders of record at the close of business on.

businesswire.com - 2026-07-15 06:12:00

[url="]Niagen Bioscience, Inc.[/url] (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy ag

gurufocus.com - 2026-07-13 09:00:00

HALIFAX, Nova Scotia--(BUSINESS WIRE)--On July 13, 2026, the Board of Directors of Emera Inc. (TSX/NYSE: EMA) declared quarterly dividends on its common shares and First Preferred Shares, each of which is payable on and after August 17, 2026 to the applicable shareholders of record at the close of business on August 3, 2026, as follows: $0.7325 per common share; $0.3094 per Series A First Preferred Share; $0.40213 per Series C First Preferred Share; $0.28125 per Series E First Preferred Share;.

businesswire.com - 2026-07-13 06:00:00

HALIFAX, Nova Scotia--(BUSINESS WIRE)--Today Emera (TSX/NYSE: EMA) announced that it will release its Q2 2026 results on Friday, August 7, 2026, before markets open. The Company will host a teleconference and webcast the same day at 9:30 a.m. Atlantic (8:30 a.m. Eastern) to discuss the results. Analysts and other interested parties in North America are invited to participate by dialing 1-800-717-1738. International parties are invited to participate by dialing 1-289-514-5100. Participants shoul.

businesswire.com - 2026-07-10 06:00:00

Johnson and Johnson presents new IMAAVYÂ (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained dise

gurufocus.com - 2026-06-26 13:00:00

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positi

gurufocus.com - 2026-06-26 08:00:00

Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) acro

gurufocus.com - 2026-06-26 08:00:00

WuXi Biologics' Suzhou Biosafety Testing Center Received Fourth EMA GMP Certification, Enabling 19 Commercial Products for the European Market

gurufocus.com - 2026-06-18 01:00:00

New TALVEYÂ (talquetamab-tgvs) plus DARZALEX FASPROÂ (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combi

gurufocus.com - 2026-06-13 07:00:00

WuXi Biologics Singapore CRDMO Hub Completes Modular Topping-Out of Drug Product Facility PR Newswire SINGAPORE,

gurufocus.com - 2026-06-04 23:00:00

Johnson and Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2

gurufocus.com - 2026-06-03 01:00:00

Johnson and Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease

gurufocus.com - 2026-06-03 01:00:00

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (MonjuviÂ/Min

gurufocus.com - 2026-05-30 09:00:00

[url="]BeOne Medicines Ltd.[/url] (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocyti

gurufocus.com - 2026-05-29 07:00:00

WuXi Biologics Achieves GMP Release of 18th Drug Product Facility, Advancing Integrated Drug Substance to Drug Product Capabilities

gurufocus.com - 2026-05-27 06:00:00

Hansa Biopharma reports positive efficacy and safety results from Idefirix European post authorization study in kidney transplantation

gurufocus.com - 2026-05-27 03:00:00

Hansa Biopharma Announces Late-Breaking Abstract from ConfIdeS Phase 3 Trial Selected for Oral Presentation at ATC 2026 PR News

gurufocus.com - 2026-05-25 23:00:00

HALIFAX, Nova Scotia--(BUSINESS WIRE)--Emera Inc. (TSX/NYSE: EMA) announced that at its Annual Meeting of Shareholders held on May 21, 2026, on a vote by ballot, each of the 11 nominees proposed as Directors and listed in its Management Information Circular dated as of March 19, 2026 were elected as Directors. The detailed results of the vote for the election of Directors are set out below. Nominee Votes For Votes Withheld   Number Percent Number Percent Scott C. Balfour 158,298,930 99.75% 390,.

businesswire.com - 2026-05-22 11:02:00

Emera Incorporated (EMA:CA) Shareholder/Analyst Call Transcript

seekingalpha.com - 2026-05-21 15:10:45

Hansa Biopharma enters into €115 million licensing agreement with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA PR New

gurufocus.com - 2026-05-19 03:00:00

HALIFAX, Nova Scotia--(BUSINESS WIRE)--Today, May 8, 2026, Emera Inc. (“Emera”) (TSX/NYSE: EMA) reported 2026 first quarter financial results1. Highlights Delivered a 7% increase in adjusted earnings per share2 (“EPS”), with $1.37 in Q1 2026, compared to $1.28 in Q1 2025, and reported EPS of $1.85 compared to $1.96 in Q1 2025. On track to deliver 2026 adjusted EPS2 growth above our earnings guidance range of 5-7%3 annualized. Capital plan on track: Deployed more than $870 million of our $4.0 bi.

businesswire.com - 2026-05-08 06:06:00

HALIFAX, Nova Scotia--(BUSINESS WIRE)--Emera Incorporated (“Emera” or the “Company”) (TSX/NYSE: EMA) announced today that after having taken into account all conversion notices received from holders of its outstanding Cumulative Minimum Rate Reset First Preferred Shares, Series J (the “Series J Shares”) by the April 30, 2026 deadline for conversion notices, less than the 1,000,000 Series J Shares required to give effect to conversions into Cumulative Floating Rate First Preferred Shares, Series.

businesswire.com - 2026-05-05 16:15:00

HALIFAX, Nova Scotia--(BUSINESS WIRE)--Today, Emera Inc. (TSX/NYSE:EMA) announced that Judy Steele, President and Chief Operating Officer of Emera Energy, will retire effective June 30, after 26 years with Emera. Over her career with Emera, Judy held several senior leadership roles, including Chief Financial Officer of Emera Inc., and spent the past 14 years leading Emera Energy. During her tenure, Emera Energy expanded its footprint across North America, increased its contribution to Emera's o.

businesswire.com - 2026-04-30 06:02:00

Novartis secures CHMP backing for Itvisma in SMA and wins WHO nod for Coartem Baby, targeting critical gaps in rare disease and infant malaria care.

zacks.com - 2026-04-27 13:20:56